Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06679946 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

StatusEnrolling by Invitation
PhasePhase 3
Started2024-12-03
View on ClinicalTrials.gov ↗

Amendment history

2026-02-19
Study Status, Contacts/Locations v11
Primary completion date2028-05-30→2028-03-31
Completion date2028-05-30→2028-03-31
Study sites72→87
2025-12-18
Study Status, Contacts/Locations v10
Study sites74→72
2025-11-13
3 amendments v7-v9
3 re-verifications since 2025-09-16, no change to tracked fields
2025-08-26
Study Status, Contacts/Locations, IPDSharing v6
Study sites75→74
2025-08-11
Study Status v5
Re-verified, no change to tracked fields
Show 4 earlier versions
2025-07-23
Study Status, Study Design v4
Primary completion date2028-06-30→2028-05-30
Completion date2028-06-30→2028-05-30
Enrollment target800→700
2025-05-14
2 amendments v2-v3
2 re-verifications since 2025-01-17, no change to tracked fields
2024-12-12
Study Status v1
Start dateestimated 2024-11-22→confirmed 2024-12-03
2024-11-06
Original filing
The purpose of this study is to obtain safety, efficacy, and pharmacodynamic data on the use of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy who continued on extended use of vutrisiran, or switched from patisiran.
Trial Details
NCT Number NCT06679946
Lead Sponsor Alnylam Pharmaceuticals
Conditions Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Enrollment 700 participants
Start Date 2024-12-03
Primary Completion 2028-03-31 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-20